Tracking the hunt for coronavirus drugs and vaccines

The National Institute of Allergy and Infectious Diseases — the agency run by Anthony Fauci — has launched the first randomized, controlled trial of remdesivir, enlisting about 1,060 patients worldwide. Results are expected in late May.

Two Chinese trials were halted this month because of a lack of enrollment, purportedly due to a lack of patients with Covid-19 as China’s outbreak wanes.

Outside of the trials, Gilead is still allowing patients to access the intravenous drug via a compassionate use program. It’s donating 1.5 million doses — enough to treat more than 140,000 patients — for use in clinical trials and compassionate use programs.